M&A Deal Summary |
|
|---|---|
| Date | 2024-02-06 |
| Target | Ayala Pharmaceuticals - AL102 |
| Sector | Life Science |
| Buyer(s) | Immunome |
| Sellers(s) | Ayala |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2006 |
| Sector | Life Science |
| Employees | 131 |
| Revenue | 9M USD (2024) |
Immunome is a biopharmaceutical company utilizing its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome’s proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Immunome was founded in 2006 and is based in Bothell, Washington.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Divestiture M&A Deals | 2 of 2 |
| State: Pennsylvania M&A | 1 of 1 |
| Country: United States M&A | 3 of 3 |
| Year: 2024 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-12-26 |
Atreca - Antibody s Related Assets and Materials
United States Atreca's Antibody's Related Assets and Materials are complementing the mission of developing innovative treatments for cancer patients. |
Buy | $6M |
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 20 |
| Revenue | 4M USD (2021) |
Ayala is a clinical-stage oncology company formed after acquiring an exclusive, worldwide license to its product candidates AL101 and AL102 from Bristol-Myers Squibb (BMS). It is focused on developing and commercializing small molecule therapeutics for patients living with rare and aggressive cancers, especially in genetically defined patient populations. Ayala is based in Wilmington, Delaware.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Pennsylvania M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2024 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-10-19 |
Advaxis
Monmouth Junction, New Jersey, United States Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology. Advaxis was incorporated in 2002 and is headquartered in Monmouth Junction, New Jersey. |
Buy | - |
